Pidilizumab: Difference between revisions

Latest revision as of 23:45, 11 December 2024

Pidilizumab

Pidilizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) pathway, which plays a crucial role in the regulation of immune responses. It is primarily investigated for its potential use in cancer immunotherapy, aiming to enhance the body's immune system to recognize and attack cancer cells.

Mechanism of Action[edit]

Pidilizumab functions by binding to the PD-1 receptor on T cells, a type of white blood cell that is essential for the immune response. The PD-1 receptor is an immune checkpoint that, when engaged by its ligands PD-L1 or PD-L2, inhibits T cell activation and proliferation. This mechanism is often exploited by cancer cells to evade immune detection. By blocking the interaction between PD-1 and its ligands, pidilizumab can potentially restore T cell activity and enhance the immune system's ability to target and destroy cancer cells.

Clinical Development[edit]

Pidilizumab has been evaluated in several clinical trials for its efficacy and safety in treating various types of cancer, including Hodgkin lymphoma, non-Hodgkin lymphoma, and melanoma. Early-phase clinical trials have shown promising results, with some patients experiencing partial or complete responses to the treatment.

Hodgkin Lymphoma[edit]

In studies involving patients with relapsed or refractory Hodgkin lymphoma, pidilizumab demonstrated an ability to induce durable responses. The treatment was generally well-tolerated, with manageable side effects.

Non-Hodgkin Lymphoma[edit]

For non-Hodgkin lymphoma, pidilizumab has been tested in combination with other therapies, such as rituximab, to evaluate its synergistic effects. Results indicated an improvement in response rates compared to standard treatments alone.

Safety and Side Effects[edit]

The safety profile of pidilizumab is similar to other immune checkpoint inhibitors. Common side effects include fatigue, rash, and diarrhea. More serious immune-related adverse events, such as pneumonitis, colitis, and hepatitis, have been observed but are less frequent.

Current Status[edit]

As of the latest updates, pidilizumab is still under investigation, and its approval status may vary by region. Researchers continue to explore its potential in combination with other immunotherapies and targeted treatments to enhance its efficacy and broaden its application in oncology.

Also see[edit]

@@ Line 1: / Line 1: @@
-<languages /><translate>
+Pidilizumab
-A humanized, immunoglobulin (Ig) G1 monoclonal antibody directed against human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Pidilizumab binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. PD-1, an inhibitory receptor belonging to the B7-receptor family expressed on activated T-lymphocytes, B-cells and NK cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.
-</translate>
+Pidilizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) pathway, which plays a crucial role in the regulation of immune responses. It is primarily investigated for its potential use in cancer immunotherapy, aiming to enhance the body's immune system to recognize and attack cancer cells.
-{{stubd}}
+==Mechanism of Action==
+Pidilizumab functions by binding to the PD-1 receptor on T cells, a type of white blood cell that is essential for the immune response. The PD-1 receptor is an immune checkpoint that, when engaged by its ligands PD-L1 or PD-L2, inhibits T cell activation and proliferation. This mechanism is often exploited by cancer cells to evade immune detection. By blocking the interaction between PD-1 and its ligands, pidilizumab can potentially restore T cell activity and enhance the immune system's ability to target and destroy cancer cells.
+==Clinical Development==
+Pidilizumab has been evaluated in several clinical trials for its efficacy and safety in treating various types of cancer, including [[Hodgkin lymphoma]], [[non-Hodgkin lymphoma]], and [[melanoma]]. Early-phase clinical trials have shown promising results, with some patients experiencing partial or complete responses to the treatment.
+===Hodgkin Lymphoma===
+In studies involving patients with relapsed or refractory Hodgkin lymphoma, pidilizumab demonstrated an ability to induce durable responses. The treatment was generally well-tolerated, with manageable side effects.
+===Non-Hodgkin Lymphoma===
+For non-Hodgkin lymphoma, pidilizumab has been tested in combination with other therapies, such as rituximab, to evaluate its synergistic effects. Results indicated an improvement in response rates compared to standard treatments alone.
+==Safety and Side Effects==
+The safety profile of pidilizumab is similar to other immune checkpoint inhibitors. Common side effects include fatigue, rash, and diarrhea. More serious immune-related adverse events, such as pneumonitis, colitis, and hepatitis, have been observed but are less frequent.
+==Current Status==
+As of the latest updates, pidilizumab is still under investigation, and its approval status may vary by region. Researchers continue to explore its potential in combination with other immunotherapies and targeted treatments to enhance its efficacy and broaden its application in oncology.
+==Also see==
+* [[Monoclonal antibody therapy]]
+* [[Cancer immunotherapy]]
+* [[Programmed cell death protein 1]]
+* [[Immune checkpoint inhibitors]]
+{{Reflist}}
+[[Category:Monoclonal antibodies]]
+[[Category:Cancer treatments]]
+[[Category:Immunotherapy]]